RedHill Biopharma to Present at World Congress of Gastroenterology

TL;DR

RedHill Biopharma presenting novel GI drug RHB-102 at major gastroenterology conference Oct 26-30.

AI Summary

RedHill Biopharma Ltd. announced on October 28, 2024, that it has been selected to present at the 2024 World Congress of Gastroenterology at ACG 2024. The presentation will focus on the company's novel gastrointestinal drug candidate, RHB-102. The congress is scheduled to take place from October 26-30, 2024, in Boston, Massachusetts.

Why It Matters

This presentation provides RedHill Biopharma with a platform to showcase its innovative gastrointestinal drug candidate, RHB-102, to a global audience of gastroenterology professionals, potentially increasing investor and partner interest.

Risk Assessment

Risk Level: low — This filing is an informational announcement about a presentation at a conference and does not contain significant financial or operational news.

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• RHB-102 (drug_candidate) — Novel gastrointestinal drug candidate
• 2024 World Congress of Gastroenterology at ACG 2024 (event) — Conference where RedHill will present
• October 28, 2024 (date) — Date of announcement
• October 26-30, 2024 (date) — Dates of the conference
• Boston, Massachusetts (location) — Location of the conference

FAQ

Filing Documents

• zk2432175.htm (6-K) — 36KB
• image00002.jpg (GRAPHIC) — 308KB
• 0001178913-24-003375.txt ( ) — 461KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: October 28, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer 2 Press Release RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND RedHill has been selected to provide a presentation to further elaborate on opaganib's potential to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) "Host Directed Therapeutics Industry Day" -- Based on reviews, feedback, and discussion, the judges selected for presentation those therapeutics that demonstrated capability in the prophylaxis, post-exposure prophylaxis, and the treatment of exposure to viruses, bacteria and toxins. The meeting is scheduled to take place October 29-30, 2024, at the United States Patent and Trademark Office in Alexandria, VA -- The JPEO-CBRND manages U.S. government investments in chemical, biological, radiological, and nuclear (CBRN) defense equipment and medical countermeasures (MCMs). The JPEO- CBRND's mission is to provide integrated, layered, chemical, biological, radiological, and nuclear defense capabilities to the Joint Force across combined Joint all-domain operations -- With multiple U.S. government collaborations for chemical and MCMs and pandemic preparedness, opaganib is a novel, host-directed, potentially broad-acting, orally administered small molecule, clinical-stage drug with demonstrated safety and efficacy profiles, being developed for various oncology, viral infections, inflammatory diseases, and chemical and nuclear/radioprotection indications TEL-AVIV, Israel / RALEIGH, NC, October 28, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDH

Forward-Looking Statements

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the potential of opaganib. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-107's late-stage development for non-hospitalized COVID-19

View Full Filing

View this 6-K filing on SEC EDGAR